查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967669

基因遞送技術市場－全球產業規模、佔有率、趨勢、機會與預測：按模式、方法、應用、地區和競爭格局分類，2021-2031年

Gene Delivery Technologies Market - Global Industry Size, Share, Trends,Opportunity and Forecast, Segmented By Mode, By Method, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因轉殖技術市場預計將從 2025 年的 34.1 億美元成長到 2031 年的 60.1 億美元，複合年成長率為 9.91%。

此領域涵蓋病毒和非病毒載體系統，旨在將治療性遺傳物質導入宿主細胞，用於治療慢性病和遺傳性疾病。主要成長動力包括全球可治療遺傳性疾病發病率的上升以及大量資金湧入生物技術研發領域。此外，建立支持性法規結構以加速新药核准是行业增长的基石。

市場概覽
預測期 2027-2031
市場規模：2025年 34.1億美元
市場規模：2031年 60.1億美元
複合年成長率：2026-2031年 9.91%
成長最快的細分市場 生物
最大的市場 北美洲

近期發展數據凸顯了該領域的蓬勃發展。正如美國基因與細胞治療學會2024年所指出的，全球治療研發管線包含超過4000種治療方法，其中基因療法佔近50%。儘管發展勢頭強勁，但該行業仍面臨著與大規模載體生產的高度複雜性和高成本相關的重大挑戰。这些生产难题仍然是阻碍市场渗透和限制商業性擴充性的主要障碍。

市場促進因素

病毒和非病毒載體系統的重大技術突破正推動市場發展，將實驗性候選藥物轉化為可商業化的治療藥物。該領域已進入關鍵的成熟階段，從早期概念驗證發展到獲得監管部門核准，涵蓋了諸如先進的腺結合病毒載體和基於CRISPR的基因編輯技術等複雜療法。這一發展進程伴隨著市場活動的空前繁榮。再生医学联盟在2024年1月报告称，美国FDA在2023年核准了7种基因疗法，创下年度批准总数新高。这些核准凸显了新一代递送平台的有效性，并推动了对新型可程式設計疗法的持续投资。例如，Arsenal Biosciences在2024年9月完成了3.25億美元的C資金籌措，用於推進其針對固態腫瘤的可程式設計細胞療法計畫。

此外，日益增多的策略聯盟和產業合作正成為推動成長的關鍵催化劑，使企業能夠應對高昂的研發成本和生產挑戰。領導企業正積極尋求併購和授權協議，以整合其專有的衣殼技術，加速臨床研發管線，而無需承擔全部內部研發負擔。此類合作對於擴大生產規模和獲得全球商業化所需的專業遞送機制至關重要。一個顯著的例子是，Astellas來製藥於2024年10月與Aviad Bio簽署了一項價值高達21.8億美元的獨家選擇權和授權合約協議，共同開發用於治療額額顳葉型失智症的基因療法。

市場挑戰

大規模載體生產固有的高昂成本和複雜性是全球基因遞送技術市場的主要阻礙因素。與傳統藥物生產不同，病毒載體的製備需要複雜的生物學過程，這些過程本身就難以標準化和規模化。這種生產規模上的限制在供應鏈中造成了嚴重的瓶頸，導致銷貨成本（COGS）增加。由於製造商難以有效率地進行商業規模生產，由此產生的經濟負擔往往轉嫁到醫療保健系統，導致保險覆蓋範圍有限和市場滲透率下降。

這種困難在近期核准治療方法的定價策略中得到了量化體現。根據再生醫學聯盟2024年的數據，單劑基因療法的批發採購成本已上漲至約310萬美元。如此高昂的價格，主要源自於載體生產所需的大量資金投入，這極大地限制了能夠獲得這些改變人生的治療方法的患者群體。因此，由於高昂的生產成本阻礙了這些治療方法的廣泛應用，市場的全部商業性潛力尚未充分發揮。

市場趨勢

將人工智慧 (AI) 整合到載體設計中，正在徹底改變基因遞送方法的發現和改進。透過利用機器學習演算法，研究人員正擺脫傳統的經驗篩檢方法，轉而採用計算設計來建構合成衣殼，從而提高組織親和性並降低免疫抗原性。這種以數據為中心的策略能夠模擬複雜的生物交互作用，顯著加快篩選出有前景的候選載體的速度，這些候選載體既能最佳化轉運效率，又能規避現有的免疫反應。主要行业参与者的战略充分体现了这项技术进步的重要性。例如，《Inc.》雜誌在2025年5月報道稱，Moderna公司已在其營運中部署了3000多個客製化AI模型，以增強mRNA藥物及其遞送系統的設計和開發。

同時，脂質奈米顆粒（LNP）作為一種非病毒載體，正迅速成為市場上的主流，用於擴大治療藥物的有效載荷。儘管病毒載體先前佔據主導地位，但LNP卓越的擴充性、安全性以及多功能性正推動其應用範圍從疫苗擴展到複雜的蛋白質替代療法和基因編輯療法。領先的製藥公司正積極建立自己的LNP平台，以確保其基因治療產品線擁有強大的遞送能力，從而避免病毒載體常見的生產瓶頸。近期一些高價值交易清晰地展現了這種策略整合的趨勢，例如艾伯維（AbbVie）計劃於2025年6月以高達21億美元的價格收購Capstan Therapeutics，這將整合用於體內細胞重編程的靶向脂質奈米顆粒技術。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章 顧客の声

第5章：全球基因遞送技術市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按方式（生物、化學、物理）
    • 依方法（體外、體內、體外）
    • 用途別（遺伝子治療、細胞治療、ワクチン、調査）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美基因遞送技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲基因傳遞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因傳遞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲基因傳遞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲基因遞送技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球基因傳遞技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc
  • Promega Corporation
  • Qiagen NV
  • Horizon Discovery Ltd.
  • OriGene Technologies, Inc.
  • Oxford Biomedica Plc
  • SignaGen Laboratories
  • Takara Bio Inc.
  • Bio-Rad Laboratories, Inc.
  • System Biosciences, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23873

The Global Gene Delivery Technologies Market is projected to expand from a valuation of USD 3.41 Billion in 2025 to reach USD 6.01 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 9.91%. This sector comprises both viral and non-viral vector systems engineered to convey therapeutic genetic materials into host cells to treat chronic diseases and genetic disorders. Primary growth stimulants include the rising global incidence of treatable genetic conditions and a substantial influx of capital investment into biotechnological research and development. Additionally, the establishment of supportive regulatory frameworks designed to accelerate the approval of novel therapeutic agents acts as a fundamental pillar for industry growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.41 Billion
Market Size 2031USD 6.01 Billion
CAGR 2026-20319.91%
Fastest Growing SegmentBiological
Largest MarketNorth America

Recent developmental data highlights the sector's vitality; as noted by the American Society of Gene & Cell Therapy in 2024, the global therapy pipeline encompassed more than 4,000 treatments, with gene therapies accounting for nearly 50% of these candidates. Despite this progressive momentum, the industry faces significant hurdles related to the high complexity and expense of large-scale vector manufacturing. These production challenges remain a substantial obstacle that threatens to hinder widespread market adoption and limit commercial scalability.

Market Driver

Significant technical breakthroughs in viral and non-viral vector systems are driving the market forward by transforming experimental candidates into commercially available treatments. The sector has reached a crucial stage of maturity, progressing from initial proof-of-concept phases to achieving regulatory success for complex modalities like advanced adeno-associated virus vectors and CRISPR-based editing. This evolution is highlighted by a record surge in market activity; the Alliance for Regenerative Medicine reported in January 2024 that the US FDA approved seven gene therapies in 2023, marking the highest annual total to date. These approvals confirm the effectiveness of next-generation delivery platforms and encourage sustained investment in novel programmable therapies, as evidenced by Arsenal Biosciences raising $325 million in Series C financing in September 2024 to advance its programmable cell therapy programs for solid tumors.

Furthermore, a rise in strategic partnerships and industry collaborations is serving as a key catalyst for growth, allowing firms to manage high development expenses and manufacturing difficulties. Biopharmaceutical leaders are actively seeking mergers and licensing deals to incorporate proprietary capsid technologies and expedite clinical pipelines without bearing the entire weight of internal research. Such alliances are critical for scaling up production and obtaining the specialized delivery mechanisms necessary for global commercialization. A notable example of this trend occurred in October 2024, when Astellas Pharma finalized an exclusive option and license agreement with AviadoBio, potentially worth up to $2.18 billion, to develop gene therapies targeting frontotemporal dementia.

Market Challenge

The substantial cost and complexity inherent in large-scale vector manufacturing present a major constraint on the Global Gene Delivery Technologies Market. In contrast to traditional pharmaceutical manufacturing, the creation of viral vectors requires intricate biological processes that are intrinsically challenging to standardize and scale. This limitation in manufacturing scalability creates significant supply chain bottlenecks and leads to a higher Cost of Goods Sold (COGS). As manufacturers encounter difficulties in efficiently producing commercial quantities, the resulting financial burden is frequently transferred to the healthcare system, resulting in restricted insurance coverage and diminished market penetration.

This difficulty is quantitatively evident in the pricing strategies for recently authorized treatments. Data from the Alliance for Regenerative Medicine in 2024 indicates that the wholesale acquisition cost for a single gene therapy treatment has climbed to approximately $3.1 million. Such elevated price points, driven by the capital-intensive requirements of vector production, severely limit the patient population capable of accessing these life-changing therapies. Consequently, the market's full commercial potential remains unrealized, as prohibitive manufacturing costs hinder the ability of these therapies to reach a wider audience.

Market Trends

The incorporation of Artificial Intelligence into vector design is revolutionizing the discovery and refinement of gene delivery vehicles. By utilizing machine learning algorithms, researchers are shifting away from traditional empirical screening methods toward the computational engineering of synthetic capsids that offer improved tissue tropism and lowered immunogenicity. This data-centric strategy enables the simulation of intricate biological interactions, vastly speeding up the identification of viable candidates capable of evading pre-existing immunity while optimizing transduction efficiency. The significance of this technological evolution is demonstrated by the strategies of key industry players; for instance, Inc. Magazine reported in May 2025 that Moderna has implemented over 3,000 customized artificial intelligence models across its operations to enhance the design and development of mRNA medicines and their delivery systems.

Concurrently, the market is witnessing an accelerated shift toward Lipid Nanoparticles (LNPs) as the preferred non-viral delivery method for an expanding array of therapeutic payloads. Although viral vectors have traditionally held dominance, the superior scalability, safety profile, and versatility of LNPs are fueling their growth beyond vaccine applications into complex protein replacement and gene editing therapies. Leading pharmaceutical companies are aggressively acquiring proprietary LNP platforms to ensure robust delivery capabilities for their genetic medicine pipelines, thereby circumventing the manufacturing bottlenecks often linked to viral vectors. This trend of strategic consolidation is exemplified by recent high-value deals, such as AbbVie's agreement in June 2025 to acquire Capstan Therapeutics for up to $2.1 billion to integrate its targeted lipid nanoparticle technology for in vivo cell reprogramming.

Key Market Players

  • Thermo Fisher Scientific, Inc
  • Promega Corporation
  • Qiagen N.V.
  • Horizon Discovery Ltd.
  • OriGene Technologies, Inc.
  • Oxford Biomedica Plc
  • SignaGen Laboratories
  • Takara Bio Inc.
  • Bio-Rad Laboratories, Inc.
  • System Biosciences, LLC

Report Scope

In this report, the Global Gene Delivery Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Delivery Technologies Market, By Mode

  • Biological
  • Chemical
  • Physical

Gene Delivery Technologies Market, By Method

  • Ex vivo
  • In vivo
  • In vitro

Gene Delivery Technologies Market, By Application

  • Gene Therapy
  • Cell Therapy
  • Vaccines
  • Research

Gene Delivery Technologies Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Delivery Technologies Market.

Available Customizations:

Global Gene Delivery Technologies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Delivery Technologies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Mode (Biological, Chemical, Physical)
    • 5.2.2. By Method (Ex vivo, In vivo, In vitro)
    • 5.2.3. By Application (Gene Therapy, Cell Therapy, Vaccines, Research)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Gene Delivery Technologies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Mode
    • 6.2.2. By Method
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Delivery Technologies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Mode
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Gene Delivery Technologies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Mode
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Gene Delivery Technologies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Mode
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Application

7. Europe Gene Delivery Technologies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Mode
    • 7.2.2. By Method
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Delivery Technologies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Mode
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Application
    • 7.3.2. France Gene Delivery Technologies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Mode
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Gene Delivery Technologies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Mode
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Gene Delivery Technologies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Mode
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Gene Delivery Technologies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Mode
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Application

8. Asia Pacific Gene Delivery Technologies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Mode
    • 8.2.2. By Method
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Delivery Technologies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Mode
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Application
    • 8.3.2. India Gene Delivery Technologies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Mode
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Gene Delivery Technologies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Mode
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Gene Delivery Technologies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Mode
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Gene Delivery Technologies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Mode
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Application

9. Middle East & Africa Gene Delivery Technologies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Mode
    • 9.2.2. By Method
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Delivery Technologies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Mode
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Gene Delivery Technologies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Mode
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Gene Delivery Technologies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Mode
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Application

10. South America Gene Delivery Technologies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Mode
    • 10.2.2. By Method
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Delivery Technologies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Mode
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Gene Delivery Technologies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Mode
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Gene Delivery Technologies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Mode
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Delivery Technologies Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Promega Corporation
  • 15.3. Qiagen N.V.
  • 15.4. Horizon Discovery Ltd.
  • 15.5. OriGene Technologies, Inc.
  • 15.6. Oxford Biomedica Plc
  • 15.7. SignaGen Laboratories
  • 15.8. Takara Bio Inc.
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. System Biosciences, LLC

16. Strategic Recommendations

17. About Us & Disclaimer